Reversal of immunoparalysis in humans in vivo: A double-blind, placebo-controlled, randomized pilot study

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 9, 2012, Pages 838-845

  Leentjens, Jenneke ^a,b   Kox, Matthijs ^a,b   Koch, Rebecca M ^a   Preijers, Frank ^a   Joosten, Leo A B ^a,b   Van Der Hoeven, Johannes G ^a   Netea, Mihai G ^a,b   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Internal Medicine ^*  (Netherlands)

Author keywords

Granulocytemacrophage colony stimulating factor; IFN ; Immunoparalysis; Lipopolysaccharide; Sepsis

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; IN VIVO STUDY; INCIDENCE; LEUKOCYTE; MALE; MONOCYTE; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY INFECTION; SEPSIS; SEPSIS INDUCED IMMUNOPARALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; DOUBLE-BLIND METHOD; ENDOTOXINS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPROMISED HOST; INTERLEUKIN-18; MALE; NETHERLANDS; PILOT PROJECTS; SEPSIS; YOUNG ADULT;

EID: 84868300033     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201204-0645OC     Document Type: Article

References (50)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
2. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003;2:391-405.
3. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008;300:413-422.
4. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, Bauer M, Riedemann NC. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011;15: R183.
5. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD II, Kreisel D, Krupnick AS, et al. Immuno-suppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306:2594-2605.
6. Hotchkiss RS, Opal S. Immunotherapy for sepsis: a new approach against an ancient foe. N Engl J Med 2010;363:87-89.
7. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, Hotchkiss RS. Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 2010;78:1582-1592.
8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
9. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, Payen D. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009;37:2746-2752.
10. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32:1175-1183.
11. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009;15:496-497.
12. Flohe SB, Agrawal H, Flohe S, Rani M, Bangen JM, Schade FU. Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol Med 2008;14:247-256.
13. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002;166:138-143.
14. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, Schneider CG, Pothmann W, Brassel AK, Schulte Am Esch J. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003;29:646-651.
15. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
16. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011;15:R58.
17. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-681.
18. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997;157:389-393.
19. Dorresteijn MJ, Draisma A, van der Hoeven JG, Pickkers P. Lipopolysaccharide-stimulated whole blood cytokine production does not predict the inflammatory response in human endotoxemia. Innate Immun 2010;16:248-253.
20. Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, Hoedemaekers CW, Pickkers P. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Crit Care Med 2011;39:1866-1870.
21. Draisma A, Pickkers P, Bouw MP, van der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009;37:1261-1267.
22. Draisma A, Dorresteijn M, Pickkers P, van der Hoeven H. The effect of systemic INOS inhibition during human endotoxemia on the devel-opment of tolerance to different TLR-stimuli. Innate Immun 2008;14: 153-159.
23. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA. Intravenous endo-toxin suppresses the cytokine response of peripheral blood mononu-clear cells of healthy humans. J Immunol 1993;151:1637-1645.
24. Heagy W, Hansen C, Nieman K, Cohen M, Richardson C, Rodriguez JL, West MA. Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify "septic" inten-sive care unit patients. Shock 2000;14:271-276, discussion 276-277.
25. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, Redl H, Roth E, Spittler A. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006;25:129-134.
26. de Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van 't Veer C, van der Poll T. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 2009;183:533-542.
27. van 't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, de Vos AF, van der Poll T. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007;179:7110-7120.
28. Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol 1995;58:373-381.
29. Bundschuh DS, Barsig J, Hartung T, Randow F, Docke WD, Volk HD, Wendel A. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol 1997;158:2862-2871.
30. Randow F, Docke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD. In vitro prevention and reversal of lipopolysaccharide desensi-tization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. J Immunol 1997;158:2911-2918.
31. Chen J, Ivashkiv LB. IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc Natl Acad Sci USA 2010;107:19438-19443.
32. Weijer S, Lauw FN, Branger J, van den Blink B, van der Poll T. Diminished interferon-gamma production and responsiveness after endotoxin administration to healthy humans. J Infect Dis 2002;186: 1748-1753.
33. Chomarat P, Rissoan MC, Banchereau J, Miossec P. Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med 1993;177: 523-527.
34. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986;323:86-89.
35. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, et al. Il-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003;4:551-556.
36. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-888.
37. Kline JN, Fisher PA, Monick MM, Hunninghake GW. Regulation of interleukin-1 receptorantagonist by Th1 andTh2cytokines. Am J Physiol 1995;269:L92-L98.
38. Sone S, Orino E, Mizuno K, Yano S, Nishioka Y, Haku T, Nii A, Ogura T. Production of IL-1 and its receptor antagonist is regulated differ-ently by IFN-gamma and IL-4 in human monocytes and alveolar macrophages. Eur Respir J 1994;7:657-663.
39. Liu JS, Amaral TD, Brosnan CF, Lee SC. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol 1998;161:1989-1996.
40. van der Poll T, van Deventer SJ, ten Cate H, Levi M, ten Cate JW. Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis 1994;169:665-667.
41. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antag- onist (IL-1ra) is an acute-phase protein. J Clin Invest 1997;99:2930-2940.
42. Bone RC. Sir Isaac Newton, sepsis, sirs, and cars. Crit Care Med 1996;24: 1125-1128.
43. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, Mougin B, Lepape A. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 2005;33:31-38, discussion 236-237.
44. Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, Camus C, Fauchet R, Thomas R, Drenou B. Monocyte human leu-kocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 2004;169:1144-1151.
45. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU, Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, et al. Monitoring temporary immunodepression by flow cytometric measure-ment of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005;51:2341-2347.
46. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, Vanhems P, Monneret G. Low monocyte human leukocyte antigen-DR is in-dependently associated with nosocomial infections after septic shock. Intensive Care Med 2010;36:1859-1866.
47. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 2003;29:1245-1252.
48. Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M. Predictive value of monocyte histocom-patibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 2003;20:1-4.
49. Wu JF, Ma J, Chen J, Ou-Yang B, Chen MY, Li LF, Liu YJ, Lin AH, Guan XD. Changes of monocyte human leukocyte antigen-DR ex-pression as a reliable predictor of mortality in severe sepsis. Crit Care 2011;15:R220.
50. Monneret G, Lepape A, Venet F. A dynamic view of MHLA-DR expression in management of severe septic patients. Crit Care 2011;15: 198.